MET and colorectal carcinoma: MET was also found to sensitize HCT1116 and SW480 cell lines to CPT‐11‐induced cytotoxicity and block the cell cycle in G1 and S phases, which indicates an innovative strategy in the treatment of CPT‐11‐resistant CRC.15